Division of Endocrinology and Diabetes Prevention and Care, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Department of Medical and Surgical Sciences (DIMEC), Alma Mater Studiorum University of Bologna, Via Massarenti 9, 40138 Bologna, Italy.
Endocrinology and Metabolism Unit, University Hospital Udine, 33100 Udine, Italy.
Int J Mol Sci. 2021 Nov 30;22(23):12975. doi: 10.3390/ijms222312975.
The advent of new insights into phosphate metabolism must urge the endocrinologist to rethink the pathophysiology of widespread disorders, such as primary hyperparathyroidism, and also of rarer endocrine metabolic bone diseases, such as hypoparathyroidism and tumor-induced hypophosphatemia. These rare diseases of mineral metabolism have been and will be a precious source of new information about phosphate and other minerals in the coming years. The parathyroid glands, the kidneys, and the intestine are the main organs affecting phosphate levels in the blood and urine. Parathyroid disorders, renal tubule defects, or phosphatonin-producing tumors might be unveiled from alterations of such a simple and inexpensive mineral as serum phosphate. This review will present all these disorders from a 'phosphate perspective'.
对磷酸盐代谢新见解的出现必然促使内分泌学家重新思考广泛存在的疾病的病理生理学，例如原发性甲状旁腺功能亢进症，以及更罕见的内分泌代谢性骨病，例如甲状旁腺功能减退症和肿瘤诱导的低磷酸盐血症。这些矿物质代谢的罕见疾病一直是，并且在未来几年内将是有关磷酸盐和其他矿物质的新信息的宝贵来源。甲状旁腺、肾脏和肠道是影响血液和尿液中磷酸盐水平的主要器官。从血清磷酸盐等简单且廉价的矿物质的改变中，可能会发现甲状旁腺疾病、肾小管缺陷或产生磷酸酯酶的肿瘤。本综述将从“磷酸盐角度”呈现所有这些疾病。
Zotero 插件